Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 66 of 66 entries
View as:

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children with Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT04833894 Org: User:
Start: 10/26/21 End: 03/31/27 Due: 03/31/28

A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus

Phase: N/A Priority: Normal
NCT ID: NCT03334058 Org: User:
Start: 10/18/17 End: 10/28/20 Due: 10/28/21

A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)

Phase: N/A Priority: Normal
NCT ID: NCT02759250 Org: User:
Start: 02/28/15 End: 06/30/18 Due: 06/30/19

A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults with Multifocal Motor Neuropathy

Phase: N/A Priority: Normal
NCT ID: NCT05225675 Org: User:
Start: 03/31/22 End: 06/04/24 Due: 06/04/25

A Study to Assess Adults with CIDP Transitioning from IVIg to Efgartigimod PH20 SC

Phase: N/A Priority: Normal
NCT ID: NCT06637072 Org: User:
Start: 12/10/24 End: 09/30/25 Due: 09/30/26

A Study to Assess the Safety of ARGX-109 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT06799416 Org: User:
Start: 01/14/25 End: 07/31/25 Due: 07/31/26

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP

Phase: N/A Priority: Normal
NCT ID: NCT03102593 Org: User:
Start: 03/13/17 End: 04/09/19 Due: 04/09/20

A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

Phase: N/A Priority: Normal
NCT ID: NCT04281472 Org: User:
Start: 04/15/20 End: 05/11/23 Due: 05/11/24

IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03457649 Org: User:
Start: 09/09/15 End: 02/21/17 Due: 02/21/18

A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants with Bullous Pemphigoid

Phase: N/A Priority: Normal
NCT ID: NCT05267600 Org: User:
Start: 06/09/22 End: 09/13/24 Due: 09/13/25

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

Phase: N/A Priority: Normal
NCT ID: NCT05979441 Org: User:
Start: 09/12/23 End: 09/30/27 Due: 09/30/28

A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

Phase: N/A Priority: Normal
NCT ID: NCT05681481 Org: User:
Start: 03/22/23 End: 03/20/25 Due: 03/20/26

A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

Phase: N/A Priority: Normal
NCT ID: NCT06909214 Org: User:
Start: 04/17/25 End: 05/31/27 Due: 05/31/28

Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children with Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT05374590 Org: User:
Start: 08/18/22 End: 09/30/28 Due: 09/30/29

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

Phase: N/A Priority: Normal
NCT ID: NCT02965573 Org: User:
Start: 12/30/16 End: 10/20/17 Due: 10/20/18

An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT04980495 Org: User:
Start: 12/16/21 End: 05/31/26 Due: 05/31/27